Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Quanta to Present Interim Analysis of First 255 Treatments Using SC+ at the 10th International Congress of the ISHD

Quanta
Posted on: 20 Sep 16

PR Newswire

ALCESTER, England, September 20, 2016

ALCESTER, England, September 20, 2016 /PRNewswire/ --

Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that it will present a poster at a moderated session on Friday 23 October at 11:30am-12:30pm at the 10th International Congress of the International Society of Haemodialysis (ISHD). The Congress will be held from Thursday 22nd to Saturday 24th September, 2016, at the Palais des congrès de Marrakech, Marrakech.

The poster will report on the results of the first 255 treatments completed using SC+ at Nottingham University Hospitals NHS Trust; Guy's and St Thomas' NHS Foundation Trust, London; and Queen Elizabeth Hospital, Birmingham.

The study, designed as an anonymised open-label, single-arm, pilot study was conducted with end-stage renal disease (ESRD) subjects receiving regular haemodialysis. A total of 43 subjects with a mean age of 62 were evaluated on a volunteer basis and each dialysis therapy was performed at an outpatient clinic. Clinical performance of SC+ was assessed by StdKt/V and URR for the study population and usability feedback was collected from nurse operators and study subjects post treatment.

SC+ performed consistently across the 255 treatments, with results demonstrating the safety and performance of SC+ as a novel HD system with acceptable clinical and technical performance in the dialysed ESRD subject population. There was no measured loss of therapy time, UF performance was acceptable, no significant usability issues were noted and there were no safety issues or device-related adverse events to report. These results demonstrate that patients dialysed with SC+ achieve adequate clearance using standard treatment regimens traditionally used in-centre. The study is ongoing.

The details of the poster at ISHD are as follows:

Title: Assessment of the safety, efficacy and usability of the Quanta SC+ haemodialysis system

Authors: Dr Charlotte Bebb, Dr Cormac Breen, Dr Clara Day, John E. Milad, Peter Hoyer, Andrew Gardner, Dr Paul May and Dr Hardip Nagra

The full poster can be viewed online here:

http://www.quantafs.com/wp-content/uploads/2016/09/SC-01161-Rev-A-Quanta-Poster-For-ISHD-Marrakech-2016.pdf

Quanta will be showcasing its high performance, compact, easy-to-use, haemodialysis system, SC+, which empowers patients through patient led care. It offers clinical efficacy and high flow rates comparable to conventional devices and is compatible with traditional treatment regimens used in-centre. It has been designed to bring flexibility to the dialysis community by allowing a greater choice in treatment frequency and location for dialysis patients.

Organized for the first time in Africa, this ISHD International Congress will not only provide a high-level scientific program on the most recent aspects in the field of haemodialysis but also allow for sharing experiences between colleagues from around the world. This meeting has the ambition to focus on scientific, practical and socio-economic challenges across diverse regions, to address the Congress theme: "For a comprehensive, equitable and sustainable access to kidney disease care". There will also be many CNE sessions and workshops for nephrologists and nurses. 

If you would like to arrange a meeting at the conference with Quanta, please contact enquiries@quantadt.com.

About SC+ 

SC+ supports patients across the continuum of care from the clinic to the home. It is the only high performance, compact, easy-to-use, haemodialysis system. SC+ offers clinical efficacy and high flow rates comparable to conventional devices and is compatible with traditional treatment regimens used in-centre. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge. This cartridge-based design approach is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE mark) and is currently being used to treat patients in the UK.

About Quanta 

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in the clinic and the home. Quanta's lead product SC+ is the only high performance, compact, easy-to-use haemodialysis system which empowers patients through patient led care.  Quanta, based in Alcester, UK, was founded in 2008 and has attracted funding from a group of leading investors including: NBGI Ventures, Wellington Partners, Seroba, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as IMI plc.

For more information please visit: http://www.quantadt.com.

For more information about Quanta, please contact:

Quanta
John E. Milad,
Chief Executive Officer
T: +44(0)1789-400043
E: enquiries@quantadt.com

Consilium Strategic Communications
Julia Wilson / Matthew Neal / Lindsey Neville
T: +44(0)203-709-5708
E: quanta@consilium-comms.com


SOURCE Quanta

PR Newswire
www.prnewswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.